News

Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1%

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.5% year on year to $181.9 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.77 per share was 15.1% above analysts’ consensus estimates.

The Pennant Group’s (NASDAQ:PNTG) Q4 Sales Top Estimates, Full-Year Sales Guidance is Optimistic

Senior living provider The Pennant Group (NASDAQ:PNTG) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 29.4% year on year to $188.9 million. The company’s full-year revenue guidance of $832.5 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP profit of $0.24 per share was in line with analysts’ consensus estimates.

DoubleVerify (NYSE:DV) Misses Q4 Revenue Estimates, Stock Drops 12.5%

Digital media measurement and analytics provider DoubleVerify (NYSE:DV) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 10.7% year on year to $190.6 million. Next quarter’s revenue guidance of $153 million underwhelmed, coming in 3% below analysts’ estimates. Its GAAP profit of $0.14 per share was 23.2% below analysts’ consensus estimates.

HP tops revenue estimates on PC market recovery; shares dip on weak profit view

HP Inc beat first-quarter revenue estimates on Thursday, driven by strength in its personal systems segment and growing demand for artificial intelligence-capable systems. Shares of the company, however, dipped more than 3% in extended trading after it projected second-quarter adjusted profit per share between 75 cents and 85 cents, lower than analysts' consensus estimate of 86 cents. PC market growth is expected to accelerate this year as the Windows 10 end-of-support deadline in October pushes hundreds of millions of PC users to refresh their devices.